Welcome to our dedicated page for Bioharvest SEC filings (Ticker: BHST), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
BioHarvest Sciences Inc. (BHST) disrupts biotechnology with its patented Botanical Synthesis platform—think yeast fermentation, but for whole-plant molecules. Investors scanning BioHarvest Sciences SEC filings want clarity on how nutraceutical sales and CDMO contracts convert breakthrough science into revenue, yet Form 10-K and 10-Q sections on R&D, scalability, and regulatory pathways can feel impenetrable.
Stock Titan delivers BioHarvest Sciences SEC filings explained simply. Our AI reads every line, then surfaces what matters: segment revenue shifts, patent portfolio updates, and consumption trends in cardiovascular health products found inside the BioHarvest Sciences annual report 10-K simplified. Need to track management moves? Receive BioHarvest Sciences Form 4 insider transactions real-time—no more manual EDGAR searches for BioHarvest Sciences insider trading Form 4 transactions.
Whether you’re researching a BioHarvest Sciences quarterly earnings report 10-Q filing, verifying BioHarvest Sciences proxy statement executive compensation, or parsing a sudden BioHarvest Sciences 8-K material events explained, the platform keeps you informed. Key features include:
- AI-powered summaries that translate dense disclosures into plain language, perfect for understanding BioHarvest Sciences SEC documents with AI.
- Real-time alerts the moment a BioHarvest Sciences executive stock transactions Form 4 posts.
- Unified access to every filing type—from R&D milestone 8-Ks to earnings report filing analysis—updated within seconds of EDGAR release.
Analysts use these insights to:
- Compare quarter-over-quarter nutraceutical margins
- Monitor insider buying ahead of new CDMO contracts
- Validate capital needs against large-scale bioreactor expansion
Skip the 200-page PDFs. Stock Titan’s AI-powered analysis distills BioHarvest Sciences disclosures into clear, decision-ready insights before the market opens.
BioHarvest Sciences Inc. (BHST) launched a primary offering of 2,485,000 common shares. The shares are priced at $7.00 each, for gross proceeds of $17,395,000, less underwriting discounts of $1,192,688, with estimated net proceeds of approximately $15,802,200. The company granted a 30‑day option to the underwriter to purchase up to 372,750 additional shares.
Shares outstanding are expected to be 19,818,430 after the offering (or 20,191,180 if the option is fully exercised). Craig‑Hallum is the sole managing underwriter, with delivery expected on or about November 10, 2025. The company plans to use the proceeds for research and development, manufacturing, marketing, advancing the CDMO business unit, debt reduction or refinancing, capital expenditures, and general corporate purposes.
BioHarvest also provided preliminary results: Q3 2025 revenue is expected to be approximately $9.1M with adjusted EBITDA between negative $0.7M and negative $0.4M. Q4 2025 guidance calls for revenue of $9.0M to $9.5M and adjusted EBITDA between negative $0.6M and $0.0M.
BioHarvest Sciences Inc. launched a preliminary prospectus supplement for a primary underwritten offering of common shares on Nasdaq under “BHST,” with Craig‑Hallum as sole managing underwriter and a 30‑day option for the underwriter to buy additional shares after effectiveness. The company, a foreign private issuer and emerging growth company, plans to use proceeds for research and development, manufacturing, marketing, advancing its CDMO business unit, debt reduction or refinancing, capital expenditures, and general corporate purposes.
Management also shared preliminary Q3 2025 results and Q4 guidance. Q3 revenue is expected at approximately $9.1M, with adjusted EBITDA in a range of ($0.7M) to ($0.4M). For Q4 2025, revenue guidance is $9.0M to $9.5M, with adjusted EBITDA between ($0.6M) and $0.0M. Recently, the company signed a CDMO agreement with Saffron Tech to develop saffron‑derived compounds; Saffron Tech will own 75% of developed compositions and related IP, while BioHarvest will hold 25% and intends to manufacture and market resulting products.
FAQ
What is the current stock price of Bioharvest (BHST)?
What is the market cap of Bioharvest (BHST)?
